ITCI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.60%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $21,306,623.17

Intra-Cellular Therapies Insider Trading History Chart

Intra-Cellular Therapies Share Price & Price History

^$131.87

+0.30 (1.20%)

As of 04/2/2025 01:00 AM ET

Days: 30 | 90 | 365

Intra-Cellular Therapies Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/4/2024	Sharon Mates	CEO	Sell	51,000	$85.80	$4,375,800.00	1,070,329
11/12/2024	Michael Halstead	President	Sell	22,869	$89.12	$2,038,085.28
8/30/2024	Sharon Mates	CEO	Sell	34,396	$72.84	$2,505,404.64	1,070,329
8/27/2024	Sharon Mates	CEO	Sell	40,513	$73.58	$2,980,946.54	1,070,329
8/23/2024	Sharon Mates	CEO	Sell	28,680	$74.46	$2,135,512.80	1,070,329
8/21/2024	Sharon Mates	CEO	Sell	53,013	$75.65	$4,010,433.45	1,070,329
8/16/2024	Mark Neumann	EVP	Sell	18,714	$75.08	$1,405,047.12	29,700
6/24/2024	Rory B. Riggs	Director	Sell	4,462	$75.57	$337,193.34	116,600
6/18/2024	Robert L. Van Nostrand	Director	Sell	20,000	$75.91	$1,518,200.00	9,690
3/11/2024	Lawrence J. Hineline	CFO	Sell	10,121	$65.96	$667,581.16
3/11/2024	Michael Halstead	EVP	Sell	7,345	$65.97	$484,549.65	19,803
3/11/2024	Sharon Mates	CEO	Sell	20,565	$65.21	$1,341,043.65	1,050,309
3/7/2024	Lawrence J. Hineline	CFO	Sell	13,132	$66.60	$874,591.20	29,700
3/7/2024	Sharon Mates	CEO	Sell	40,712	$66.50	$2,707,348.00	1,050,309
3/7/2024	Suresh K. Durgam	EVP	Sell	6,450	$66.56	$429,312.00	16,170
2/26/2024	Joel S. Marcus	Director	Sell	26,328	$68.68	$1,808,207.04	39,662
2/26/2024	Lawrence J. Hineline	CFO	Sell	13,337	$69.43	$925,987.91
2/26/2024	Michael Halstead	EVP	Sell	7,907	$69.53	$549,773.71	29,700
2/26/2024	Sharon Mates	CEO	Sell	22,590	$69.79	$1,576,556.10	1,050,309
1/18/2024	Sharon Mates	CEO	Sell	67,917	$65.19	$4,427,509.23	1,050,309
1/16/2024	Sharon Mates	CEO	Sell	75,361	$67.25	$5,068,027.25	1,050,309
1/11/2024	Michael Halstead	EVP	Sell	50,000	$66.83	$3,341,500.00
1/2/2024	Suresh K. Durgam	EVP	Sell	62,282	$70.60	$4,397,109.20
12/13/2023	Suresh K. Durgam	EVP	Sell	21,262	$65.00	$1,382,030.00
11/6/2023	Mark Neumann	EVP	Sell	42,393	$55.63	$2,358,322.59	29,700
9/18/2023	Sharon Mates	CEO	Sell	55,587	$53.76	$2,988,357.12	1,094,722
8/7/2023	Mark Neumann	EVP	Sell	55,300	$58.79	$3,251,087.00	45,339
7/17/2023	Suresh K. Durgam	EVP	Sell	1,842	$65.00	$119,730.00	21,262
6/14/2023	Lawrence J. Hineline	CFO	Sell	81,854	$63.97	$5,236,200.38
4/17/2023	Robert L. Van Nostrand	Director	Sell	10,000	$63.00	$630,000.00	9,345
3/28/2023	Mark Neumann	EVP	Sell	15,604	$54.31	$847,453.24	45,339
3/13/2023	Lawrence J. Hineline	CFO	Sell	5,582	$44.93	$250,799.26
3/13/2023	Sharon Mates	CEO	Sell	20,565	$44.99	$925,219.35	1,130,309
3/13/2023	Suresh K. Durgam	EVP	Sell	7,344	$45.04	$330,773.76	23,104
3/10/2023	Lawrence J. Hineline	CFO	Sell	15,663	$43.06	$674,448.78
3/10/2023	Mark Neumann	EVP	Sell	8,550	$43.34	$370,557.00	57,357
3/10/2023	Sharon Mates	CEO	Sell	41,770	$43.15	$1,802,375.50	1,130,309
3/1/2023	Mark Neumann	EVP	Sell	7,241	$50.01	$362,122.41	49,199
2/24/2023	Lawrence J. Hineline	CFO	Sell	7,455	$47.03	$350,608.65
2/24/2023	Mark Neumann	EVP	Sell	4,046	$47.12	$190,647.52	56,440
2/24/2023	Sharon Mates	CEO	Sell	22,590	$47.03	$1,062,407.70	1,100,309
2/24/2023	Suresh K. Durgam	SVP	Sell	7,906	$47.14	$372,688.84	23,104
2/21/2023	Lawrence J. Hineline	CFO	Sell	10,443	$46.82	$488,941.26
2/21/2023	Mark Neumann	EVP	Sell	3,898	$47.01	$183,244.98	52,580
2/21/2023	Sharon Mates	CEO	Sell	27,848	$46.83	$1,304,121.84	1,100,309
2/21/2023	Suresh K. Durgam	SVP	Sell	8,354	$46.84	$391,301.36	23,104
2/17/2023	Lawrence J. Hineline	CFO	Sell	53,968	$49.83	$2,689,225.44
12/19/2022	Joel S. Marcus	Director	Sell	5,000	$50.82	$254,100.00	29,233
12/13/2022	Sharon Mates	CEO	Sell	33,083	$55.00	$1,819,565.00	1,100,309
12/1/2022	Michael Halstead	EVP	Sell	50,000	$53.73	$2,686,500.00
9/21/2022	Lawrence J. Hineline	CFO	Sell	65,164	$45.63	$2,973,433.32
8/11/2022	Robert L. Van Nostrand	Director	Sell	30,000	$57.13	$1,713,900.00	9,043

See Full Table

SEC Filings (Institutional Ownership Changes) for Intra-Cellular Therapies (NASDAQ:ITCI)

92.33% of Intra-Cellular Therapies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Intra-Cellular Therapies Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/13/2025	Northern Trust Corp	634,535	$83.71M	0.0%	+4.1%	0.596%
5/13/2025	Versor Investments LP	56,656	$7.47M	1.2%	N/A	0.053%
5/13/2025	Algert Global LLC	59,701	$7.88M	0.2%	+140.1%	0.056%
5/13/2025	State of New Jersey Common Pension Fund D	33,199	$4.38M	0.0%	-9.8%	0.031%
5/13/2025	American Century Companies Inc.	10,773	$1.42M	0.0%	-96.6%	0.010%
5/13/2025	Sei Investments Co.	191,628	$25.28M	0.2%	-3.1%	0.180%
5/13/2025	Kovitz Investment Group Partners LLC	2,202	$0.29M	0.0%	N/A	0.002%
5/13/2025	Russell Investments Group Ltd.	8,336	$1.10M	0.0%	-74.2%	0.008%
5/13/2025	HighTower Advisors LLC	3,858	$0.51M	0.0%	-7.7%	0.004%
5/12/2025	Longfellow Investment Management Co. LLC	574	$76K	0.0%	N/A	0.001%
5/12/2025	Nuveen LLC	304,125	$40.12M	0.0%	N/A	0.286%
5/12/2025	Invesco Ltd.	85,066	$11.22M	0.0%	-97.2%	0.080%
5/12/2025	Covestor Ltd	1,233	$0.16M	0.1%	-41.3%	0.001%
5/12/2025	Wolverine Asset Management LLC	40,265	$5.31M	0.1%	N/A	0.038%
5/12/2025	National Bank of Canada FI	133,000	$17.55M	0.0%	N/A	0.125%
5/12/2025	Swiss National Bank	185,200	$24.43M	0.0%	-1.0%	0.174%
5/12/2025	Mitsubishi UFJ Asset Management Co. Ltd.	268	$35K	0.0%	+152.8%	0.000%
5/12/2025	Maryland State Retirement & Pension System	4,810	$0.64M	0.0%	-18.2%	0.005%
5/9/2025	Headlands Technologies LLC	6,637	$0.88M	0.1%	-65.2%	0.006%
5/9/2025	Deutsche Bank AG	693,427	$91.48M	0.0%	-10.6%	0.651%
5/9/2025	Chicago Capital Management LLC	90,200	$11.90M	7.4%	N/A	0.085%
5/9/2025	Charles Schwab Investment Management Inc.	895,664	$118.16M	0.0%	-1.2%	0.841%
5/9/2025	Vanguard Group Inc.	9,519,968	$1.26B	0.0%	-2.1%	8.937%
5/9/2025	West Michigan Advisors LLC	1,552	$0.21M	0.1%	N/A	0.001%
5/9/2025	ABC Arbitrage SA	40,679	$5.37M	1.0%	N/A	0.038%
5/9/2025	Cary Street Partners Financial LLC	1,500	$0.20M	0.0%	N/A	0.001%
5/9/2025	Sfmg LLC	1,748	$0.23M	0.0%	N/A	0.002%
5/9/2025	ING Groep NV	376,800	$49.71M	0.3%	+2,914.4%	0.354%
5/9/2025	Earned Wealth Advisors LLC	1,664	$0.22M	0.0%	N/A	0.002%
5/9/2025	DCF Advisers LLC	3,500	$0.46M	0.2%	-96.5%	0.003%
5/9/2025	J. Safra Sarasin Holding AG	8,799	$1.16M	0.0%	-71.2%	0.008%
5/9/2025	Bank of Nova Scotia	11,400	$1.50M	0.0%	N/A	0.011%
5/9/2025	PNC Financial Services Group Inc.	2,516	$0.33M	0.0%	-68.7%	0.002%
5/8/2025	Commerce Bank	2,431	$0.32M	0.0%	-65.7%	0.002%
5/8/2025	Jefferies Financial Group Inc.	29,909	$3.95M	0.0%	N/A	0.028%
5/8/2025	Alberta Investment Management Corp	79,000	$10.42M	0.1%	+1,449.0%	0.074%
5/8/2025	US Bancorp DE	2,195	$0.29M	0.0%	-39.4%	0.002%
5/8/2025	Alpine Associates Management Inc.	719,500	$94.92M	5.0%	N/A	0.675%
5/8/2025	Vestcor Inc	128,319	$16.93M	0.6%	N/A	0.120%
5/8/2025	XTX Topco Ltd	2,085	$0.28M	0.0%	N/A	0.002%
5/8/2025	GSA Capital Partners LLP	7,376	$0.97M	0.1%	N/A	0.007%
5/7/2025	Essex Investment Management Co. LLC	49,717	$6.56M	1.4%	-12.6%	0.047%
5/7/2025	Zurcher Kantonalbank Zurich Cantonalbank	25,079	$3.31M	0.0%	+1.8%	0.024%
5/7/2025	Kapitalo Investimentos Ltda	78,586	$10.37M	2.1%	N/A	0.074%
5/7/2025	Burren Capital Advisors Ltd	20,074	$2.65M	9.5%	N/A	0.019%
5/7/2025	Skandinaviska Enskilda Banken AB publ	35,000	$4.62M	0.0%	-87.4%	0.033%
5/7/2025	J.P. Marvel Investment Advisors LLC	63,771	$8.41M	1.5%	-0.7%	0.060%
5/6/2025	Assetmark Inc.	281	$37K	0.0%	-87.7%	0.000%
5/6/2025	Cetera Investment Advisers	3,487	$0.46M	0.0%	-21.8%	0.003%
5/6/2025	Pinnacle Associates Ltd.	135,344	$17.86M	0.3%	-6.4%	0.127%
5/6/2025	Readystate Asset Management LP	507,200	$66.91M	2.2%	N/A	0.476%
5/6/2025	Universal Beteiligungs und Servicegesellschaft mbH	11,251	$1.48M	0.0%	-88.2%	0.011%
5/6/2025	Tabor Asset Management LP	39,129	$5.16M	1.3%	N/A	0.037%
5/5/2025	GW&K Investment Management LLC	141,109	$18.62M	0.2%	-89.8%	0.132%
5/5/2025	IFP Advisors Inc	4,440	$0.59M	0.0%	-7.1%	0.004%
5/5/2025	St. Louis Trust Co	163,488	$21.57M	3.1%	N/A	0.153%
5/5/2025	Tabor Asset Management LP	39,129	$5.16M	2.0%	N/A	0.037%
5/2/2025	Kintayl Capital LP	11,516	$1.52M	1.1%	N/A	0.011%
5/2/2025	Victory Capital Management Inc.	11,938	$1.58M	0.0%	-80.8%	0.011%
5/2/2025	Apollon Wealth Management LLC	3,671	$0.48M	0.0%	N/A	0.003%
5/2/2025	Signaturefd LLC	813	$0.11M	0.0%	+41.1%	0.001%
5/1/2025	CWM LLC	16,812	$2.22M	0.0%	+18.6%	0.016%
5/1/2025	New York State Common Retirement Fund	55,855	$7.37M	0.0%	-27.0%	0.052%
5/1/2025	Arizona State Retirement System	27,425	$3.62M	0.0%	-0.5%	0.026%
5/1/2025	Ballentine Partners LLC	2,180	$0.29M	0.0%	N/A	0.002%
5/1/2025	Xponance Inc.	14,093	$1.86M	0.0%	+3.6%	0.013%
4/30/2025	Cerity Partners LLC	20,446	$2.70M	0.0%	-50.7%	0.019%
4/30/2025	Nisa Investment Advisors LLC	2,224	$0.29M	0.0%	-16.9%	0.002%
4/30/2025	Trium Capital LLP	102,105	$13.47M	1.7%	N/A	0.096%
4/30/2025	M&T Bank Corp	4,061	$0.54M	0.0%	-35.5%	0.004%
4/30/2025	Brown Advisory Inc.	2,147	$0.28M	0.0%	-49.6%	0.002%
4/30/2025	China Universal Asset Management Co. Ltd.	21,328	$2.81M	0.3%	-5.1%	0.020%
4/30/2025	Crossmark Global Holdings Inc.	1,603	$0.21M	0.0%	N/A	0.002%
4/29/2025	Envestnet Asset Management Inc.	6,349	$0.84M	0.0%	-95.2%	0.006%
4/29/2025	Concurrent Investment Advisors LLC	5,557	$0.73M	0.0%	N/A	0.005%
4/29/2025	Bank of New York Mellon Corp	350,044	$46.18M	0.0%	-2.5%	0.329%
4/29/2025	GF Fund Management CO. LTD.	2,714	$0.36M	0.0%	+21.9%	0.003%
4/28/2025	Principal Financial Group Inc.	6,925	$0.91M	0.0%	-98.7%	0.007%
4/28/2025	Teacher Retirement System of Texas	25,732	$3.40M	0.0%	-8.6%	0.024%
4/28/2025	Cannon Global Investment Management LLC	5,112	$0.67M	1.2%	N/A	0.005%
4/28/2025	CIBRA Capital Ltd	416,218	$54.91M	18.8%	N/A	0.391%
4/25/2025	Amalgamated Bank	7,452	$0.98M	0.0%	+8.2%	0.007%
4/25/2025	KBC Group NV	4,096	$0.54M	0.0%	+8.5%	0.004%
4/25/2025	Sumitomo Mitsui Trust Group Inc.	2,407	$0.32M	0.0%	N/A	0.002%
4/24/2025	Jaffetilchin Investment Partners LLC	2,972	$0.39M	0.0%	-42.8%	0.003%
4/23/2025	Syquant Capital Sas	266,228	$35.12M	24.9%	N/A	0.250%
4/22/2025	Advisor Resource Council	1,953	$0.26M	0.0%	N/A	0.002%
4/17/2025	QRG Capital Management Inc.	3,288	$0.43M	0.0%	N/A	0.003%
4/17/2025	Janney Montgomery Scott LLC	3,191	$0.42M	0.0%	-3.8%	0.003%
4/16/2025	Wealth Enhancement Advisory Services LLC	12,576	$1.66M	0.0%	+4.7%	0.012%
4/15/2025	Handelsbanken Fonder AB	29,300	$3.87M	0.0%	+8.1%	0.028%
4/15/2025	SG Americas Securities LLC	94,039	$12.41M	0.0%	+628.0%	0.088%
4/15/2025	Sonora Investment Management Group LLC	80,763	$10.65M	0.8%	-7.1%	0.076%
4/14/2025	Pallas Capital Advisors LLC	3,942	$0.52M	0.0%	+23.9%	0.004%
4/14/2025	Farther Finance Advisors LLC	884	$0.12M	0.0%	+452.5%	0.001%
4/14/2025	OLD National Bancorp IN	3,500	$0.46M	0.0%	-27.1%	0.003%
4/11/2025	SeaCrest Wealth Management LLC	1,900	$0.25M	0.0%	N/A	0.002%
4/9/2025	Merit Financial Group LLC	2,798	$0.37M	0.0%	+13.5%	0.003%
4/8/2025	Rhumbline Advisers	125,239	$16.52M	0.0%	-0.3%	0.118%
4/7/2025	GAMMA Investing LLC	98,940	$130.52M	0.0%	+12,952.8%	0.093%

Data available starting January 2016

See Full Table

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $131.87

$131.87

50 Day Range

MA: $131.74

$131.24

$131.92

52 Week Range

Now: $131.87

$64.09

$131.98

Volume

N/A

Average Volume

1,492,905 shs

Market Capitalization

$14.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Who are the company insiders with the largest holdings of Intra-Cellular Therapies?: Intra-Cellular Therapies' top insider shareholders include:
Sharon Mates (CEO)
Rory B Riggs (Director)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Michael Halstead (EVP)
Suresh K Durgam (EVP)
Nostrand Robert L Van (Director)
Michael Halstead (President)
Suresh K Durgam (EVP)
Learn More about top insider investors at Intra-Cellular Therapies.
Who are the major institutional investors of Intra-Cellular Therapies?: Intra-Cellular Therapies' top institutional shareholders include:
Vanguard Group Inc. — 8.94%
Charles Schwab Investment Management Inc. — 0.84%
Alpine Associates Management Inc. — 0.68%
Deutsche Bank AG — 0.65%
Readystate Asset Management LP — 0.48%
CIBRA Capital Ltd — 0.39%
Learn More about top institutional investors of Intra-Cellular Therapies stock.
Which institutional investors are selling Intra-Cellular Therapies stock?: In the previous quarter, ITCI stock was sold by these institutional investors:
Invesco Ltd.
GW&K Investment Management LLC
Principal Financial Group Inc.
Skandinaviska Enskilda Banken AB publ
Vanguard Group Inc.
Envestnet Asset Management Inc.
DCF Advisers LLC
Universal Beteiligungs und Servicegesellschaft mbH
During the last year, company insiders that have sold Intra-Cellular Therapies company stock include:
Sharon Mates (CEO)
Rory B Riggs (Director)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Learn More investors selling Intra-Cellular Therapies stock.
Which institutional investors are buying Intra-Cellular Therapies stock?: During the last quarter, ITCI stock was acquired by institutional investors including:
Alpine Associates Management Inc.
Readystate Asset Management LP
CIBRA Capital Ltd
ING Groep NV
Nuveen LLC
Syquant Capital Sas
St. Louis Trust Co
Picton Mahoney Asset Management